August 2013

Dear shareholders and prospective shareholders,

In early August, CRH attended 2013 GI Outlook: The Practice Management Conference in Chicago, IL. This was our third year exhibiting at the meeting, which is attended by gastroenterologists (GIs), nurse managers and practice administrators from across the U.S.

During our time there, we were able to speak with trained and prospective GIs about either introducing the procedure for the first time, or provide clinical advice and tips on how to grow their existing business. This conference also provided us with the opportunity to speak with senior administrative staff at both large and small groups, many of whom view our procedure as beneficial to their patients and a significant revenue stream for their practice.

Pilot Scheduling Program

This summer, we launched a test program designed to help GI practices schedule patients for hemorrhoid treatment after their colonoscopies where the disease has been diagnosed. In many cases, staff aren’t able to dedicate sufficient time for patient follow up and this program allows for efficient and effective scheduling without impeding on existing staff resources.

The program we launched utilizes information from the practice’s electronic medical records database to facilitate a call back – ultimately leading to a scheduled patient appointment with the GIs for treatment with the O’Regan System.

Bay Street Marketing

Later in August, we marketed the Company on Bay Street. The audience for our 1X1 meetings consisted of sell side analysts, brokers and fund managers. Two things became apparent from the meetings:

1. The brokers and fund managers seemed impressed by the consistent operational results that CRH has recorded over the past several quarters.

2. As the Company’s market cap grows, the interest in CRH Medical is starting to come from more diverse sources. Case in point: a quantitative fund (an investor who invests in what their computer programs tell them to invest in), agreed to take a look at CRH Medical after showing tepid interest when the market cap was at lower levels.
We look forward to sharing the September edition of the CRH Investor Bulletin with you, and as always, we appreciate your interest and support.

Adam Peeler
Media and Investor Relations
TMX Equicom
416.815.0700 x 225

We're a stable, profitable company respected by both patients and physicians. Learn more »